Printer Friendly

ALTEON PRESENTS AMINOUGUANIDINE PIVOTAL PHASE II/III CLINICAL PROGRAM TO FDA

 ALTEON PRESENTS AMINOUGUANIDINE PIVOTAL PHASE II/III
 CLINICAL PROGRAM TO FDA
 NORTHVALE, N.J., June 2 /PRNewswire/ -- Alteon Inc. (NASDAQ: ALTN) today announced that detailed draft protocols for pivotal Phase II/III clinical studies with its lead compound, aminoguanidine, in diabetic nephropathy and end-stage renal disease (dialysis) patients were presented yesterday to the FDA. These protocols, together with the pre- clinical and Phase I human clinical data packages, were submitted to the FDA earlier in the spring.
 The company said that the FDA indicated they would respond soon with their recommendations following their internal review of the programs.
 Alteon is a development stage pharmaceutical company engaged in the discovery and development of products for the treatment of the complication of diabetes and aging. These products are designed to inhibit, reverse and measure damage to cells, tissues and organs caused by advanced glycosylation end-products (AGEs) which are formed as a result of glucose in the body's circulatory system.
 -0- 6/2/92
 /CONTACT: Charles A. Faden, president and CEO of Alteon, 201-784-1010, or Susan A. Noonan of Noonan/Russo Communications, Inc., 212-979-9180, for Alteon/
 (ALTN) CO: Alteon Inc. ST: New Jersey IN: MTC SU:


TQ-SH -- NY012 -- 6074 06/02/92 09:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1992
Words:202
Previous Article:STEWART ENTERPRISES REPORTS SECOND QUARTER 1992 RESULTS
Next Article:GALAXY FOODS COMPANY ISSUES INSURANCE UPDATE
Topics:


Related Articles
FDA RESPONDS FAVORABLY TO ALTEON'S PHASE III CLINICAL DEVELOPMENT PROGRAM
PIMAGEDINE TESTING BEGINS IN TYPE II DIABETICS WITH KIDNEY DISEASE
ALTEON IDENTIFIES NEW PRODUCT AS POTENTIAL TREATMENT OF DIABETIC COMPLICATIONS
ALTEON ANNOUNCES PHASE II CLINICAL TRIALS HAVE BEGUN; PIMAGEDINE NOW IN 5 CLINICAL TRIALS TO TREAT DIABETIC COMPLICATIONS
Enrollment Completed in Alteon's First Phase III Clinical Trial of Pimagedine
Alteon and Genentech to Collaborate on Therapy for Diabetic Complications
Alteon Begins Human Testing of Compound Found in Preclinical Studies to Improve Cardiovascular Function
An overview of the drug development process.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters